About Neuromedin-B receptor
Neuromedin-B receptor (NMBR) is a protein
from Homo sapiens identified by UniProt accession
P28336, 390 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | Neuromedin-B receptor |
|---|
| UniProt accession | P28336 |
|---|
| Gene | NMBR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 390 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (71)
Diseases linked to this target (Open Targets).
- forced expiratory volume · score 0.29
- neurodegenerative disease · score 0.27
- glioblastoma multiforme · score 0.26
- FEV/FVC ratio · score 0.26
- ovarian cancer · score 0.26
- breast adenocarcinoma · score 0.25
- vital capacity · score 0.22
- brain measurement · score 0.22
- eye measurement · score 0.16
- head and neck squamous cell carcinoma · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P28336-F1 | alphafold | PREDICTED | 79.29 | — |
Amino-acid sequence (390 residues)
MPSKSLSNLS VTTGANESGS VPEGWERDFL PASDGTTTEL VIRCVIPSLY LLIITVGLLG NIMLVKIFIT NSAMRSVPNI FISNLAAGDL LLLLTCVPVD ASRYFFDEWM FGKVGCKLIP VIQLTSVGVS VFTLTALSAD RYRAIVNPMD MQTSGALLRT CVKAMGIWVV SVLLAVPEAV FSEVARISSL DNSSFTACIP YPQTDELHPK IHSVLIFLVY FLIPLAIISI YYYHIAKTLI KSAHNLPGEY NEHTKKQMET RKRLAKIVLV FVGCFIFCWF PNHILYMYRS FNYNEIDPSL GHMIVTLVAR VLSFGNSCVN PFALYLLSES FRRHFNSQLC CGRKSYQERG TSYLLSSSAV RMTSLKSNAK NMVTNSVLLN GHSMKQEMAL
Explore Neuromedin-B receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets